Lunai Bioworks (NASDAQ:LNAI) Issues Earnings Results

Lunai Bioworks (NASDAQ:LNAI) released its quarterly earnings data on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.03 million for the quarter.

Lunai Bioworks Price Performance

Shares of NASDAQ LNAI traded down $0.08 during trading hours on Tuesday, hitting $1.03. 30,340 shares of the company’s stock were exchanged, compared to its average volume of 1,188,176. Lunai Bioworks has a 1-year low of $0.88 and a 1-year high of $13.28. The stock has a market capitalization of $4.67 million, a price-to-earnings ratio of -2.57 and a beta of 0.37. The company’s 50-day moving average price is $2.08 and its 200-day moving average price is $2.53.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lunai Bioworks in a research report on Friday, October 2nd. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.